Bionano Genomics, Inc. (BNGO)
After hours:
- GlobeNewswire
Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs). Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive and accurate identification of genetic abnormalities in MM samples is cr
- GlobeNewswire
Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series WarrantsSAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 17,513,136 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.571 per sha
- GlobeNewswire
Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series WarrantsSAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the purchase and sale of an aggregate of 17,513,136 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.571 per share of common
